Company intelligence / Profile preview

Covanos

Atlanta, Georgia, United States

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

Covanos has developed C-HEART technology that uses advanced mathematical methods and computational fluid dynamics to non-invasively assess the hemodynamic significance of blood vessel obstructions, helping guide clinical decisions regarding revascularization and determining the risk of future coronary events[3].

Therapeutic areas: Cardiovascular
Modalities: Computational fluid dynamicsmathematical methods
Industry: Medical Imaging

Drug pipeline

3 assets

prexigebersen

Phase 2

Indications: Acute myeloid leukemia, Chronic myeloid leukemia, Myelodysplastic syndrome

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Covanos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Covanos.

Explore the full profile